A manufacturing facility in Wisconsin, USA, has been purchased by Eli Lilly (NYSE: LLY) in order to support growing demand for its medicines.
Nexus Pharmaceuticals, a sterile manufacturer supplying the pharmaceutical industry, has agreed to sell the US Food and Drug Administration-approved facility for an undisclosed sum.
The site will be used to further expand Lilly's global injectable product manufacturing network, with production at the facility expected to kick off at the end of 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze